These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 27673603)

  • 1. Clinically Guided Warfarin Dose Versus Genotyping In Early Achievement Of Stable Anticoagulant Effect Of Warfarin.
    Makar-Ausperger K; Bozina N; Erdeljic Turk V; Likic R; Radacic Aumiler M; Ganoci L; Francetic I
    Clin Ther; 2016 Oct; 38(10S):e10. PubMed ID: 27673603
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials.
    Wang ZQ; Zhang R; Zhang PP; Liu XH; Sun J; Wang J; Feng XF; Lu QF; Li YG
    J Cardiovasc Pharmacol; 2015 Apr; 65(4):364-70. PubMed ID: 25551322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is personalized medicine a dream or a reality?
    Morse BL; Kim RB
    Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
    Lu Y; Branstad R; Karim RM; Asinger RW
    J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study.
    Mahé I; Bertrand N; Drouet L; Bal Dit Sollier C; Simoneau G; Mazoyer E; Caulin C; Bergmann JF
    Haematologica; 2006 Dec; 91(12):1621-7. PubMed ID: 17145598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers.
    Rahimy M; Hallén B; Narang P
    Arzneimittelforschung; 2002; 52(12):890-5. PubMed ID: 12572529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral anticoagulant use in patients with atrial fibrillation].
    Ertaş F; Duygu H; Acet H; Eren NK; Nazli C; Ergene AO
    Turk Kardiyol Dern Ars; 2009 Apr; 37(3):161-7. PubMed ID: 19553738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery.
    Douketis JD; Woods K; Foster GA; Crowther MA
    Thromb Haemost; 2005 Sep; 94(3):528-31. PubMed ID: 16268467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased anticoagulant activity of warfarin used in combination with doxifluridine.
    Nakajima M; Genda T; Suehira M; Satoh H; Miki A; Hori S; Sawada Y
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):969-72. PubMed ID: 20107800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initiation of oral anticoagulant treatment: comparison between different dosage regimens of warfarin and phenprocoumon].
    Kemkes-Matthes B; Matzdorff A; Heidt M; Winkler L; Bernardo A; Bernardo A
    Hamostaseologie; 2002 May; 22(2):47-51. PubMed ID: 12193977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin.
    MacCallum P; Madhani M; Mt-Isa S; Ashby D
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):786-9. PubMed ID: 17111459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a potential tigecycline-warfarin drug interaction.
    Zimmerman JJ; Raible DG; Harper DM; Matschke K; Speth JL
    Pharmacotherapy; 2008 Jul; 28(7):895-905. PubMed ID: 18576904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of plasma protein binding on the anticoagulant action of warfarin in rats.
    Yacobi A; Levy G
    Res Commun Chem Pathol Pharmacol; 1975 Oct; 12(2):405-8. PubMed ID: 1197921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients].
    Isaza C; Beltrán L; Henao J; Porras G; Pinzón A; Vallejos A; Machado J
    Biomedica; 2010; 30(3):410-20. PubMed ID: 21713343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.